Clinical Benefits of Telotristat Ethyl in Patients With Neuroendocrine Tumors and Low Bowel Movement Frequency: An Observational Patient-Reported Outcomes Study. Issue 3 (March 2020)

• Record Type: Journal Article
• Authors: Benson, Al B.; Strosberg, Jonathan; Joish, Vijay N.; Dharba, Samyukta; Sapre, Dipa; Lapuerta, Pablo
• Is Part Of: Pancreas. Volume 49:Issue 3(2020)
• Publication Date: 2020-03
• Subjects: neuroendocrine tumors -- carcinoid syndrome diarrhea -- telotristat ethyl -- somatostatin analogs; Pancreas -- Diseases -- Periodicals; Pancreas -- Periodicals; Neuroendocrine tumors -- Periodicals; 616.37005
• DOI: 10.1097/MPA.0000000000001496
• Languages: English
• ISSNs: 0885-3177

Abstract

Abstract : Objectives: We evaluated carcinoid syndrome (CS) symptoms and the real-world effectiveness of telotristat ethyl (TE) among patients with ⩽3 bowel movements (BM) per day. Methods: Patients with CS initiating TE between March and November 2017 could participate in a nurse support program collecting demographic and CS symptom data before TE initiation (baseline) and during ≥1 monthly follow-up within 3 months. Symptoms for patients averaging ⩽3 BM/d at baseline were evaluated using pre/post–Student t tests. Results: Sixty-eight patients reported ⩽3 BM/d at baseline. Symptom burden was high and similar to participants with higher daily BM frequency. After 3 months of TE, most patients reported stable or improved symptoms with significant improvements in urgency (88%; mean [SD], –13.2 [32.2]), stool consistency (88%; −1.3 [2.0]), BMs per day (81%; −0.2 [1.2]), abdominal pain (86%; −13.7 [25.8]), nausea (85%; −30.9 [35.7]), and daily flushing episodes (83%; −1.7 [4.4]; all except BMs per day, P < 0.05). Conclusions: This analysis illustrates high CS symptom burden among patients with relatively low daily BM frequency. After initiating TE, patients reported significant improvements in urgency, stool consistency, abdominal pain, nausea, and flushing episodes. Clinicians and population health managers should consider CS symptom burden beyond daily BM frequency when evaluating treatment selection.